Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A review of national guidelines for management of COPD in Europe

M. Miravitlles, C. Vogelmeier, N. Roche, D. Halpin, J. Cardoso, AG. Chuchalin, H. Kankaanranta, T. Sandström, P. Śliwiński, J. Zatloukal, F. Blasi,

. 2016 ; 47 (2) : 625-37. [pub] 20160121

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000601

The quality of care can be improved by the development and implementation of evidence-based treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them.This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators.There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of long-acting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000601
003      
CZ-PrNML
005      
20170117122655.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/13993003.01170-2015 $2 doi
024    7_
$a 10.1183/13993003.01170-2015 $2 doi
035    __
$a (PubMed)26797035
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Miravitlles, Marc $u Pneumology Dept, University Hospital Vall d'Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain mmiravitlles@vhebron.net.
245    12
$a A review of national guidelines for management of COPD in Europe / $c M. Miravitlles, C. Vogelmeier, N. Roche, D. Halpin, J. Cardoso, AG. Chuchalin, H. Kankaanranta, T. Sandström, P. Śliwiński, J. Zatloukal, F. Blasi,
520    9_
$a The quality of care can be improved by the development and implementation of evidence-based treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them.This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators.There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of long-acting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    _2
$a bronchodilatancia $x terapeutické užití $7 D001993
650    _2
$a Česká republika $7 D018153
650    _2
$a management nemoci $7 D019468
650    _2
$a Anglie $7 D004739
650    _2
$a Evropa $7 D005060
650    _2
$a medicína založená na důkazech $7 D019317
650    _2
$a expektorancia $x terapeutické užití $7 D005100
650    _2
$a Finsko $7 D005387
650    _2
$a Francie $7 D005602
650    _2
$a Německo $7 D005858
650    _2
$a lidé $7 D006801
650    _2
$a Itálie $7 D007558
650    _2
$a plánování péče o pacienty $7 D010347
650    _2
$a výběr pacientů $7 D018579
650    _2
$a Polsko $7 D011044
650    _2
$a Portugalsko $7 D011174
650    12
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a chronická obstrukční plicní nemoc $x diagnóza $x farmakoterapie $7 D029424
650    _2
$a Rusko $7 D012426
650    _2
$a Španělsko $7 D013030
650    _2
$a Švédsko $7 D013548
650    _2
$a Wales $7 D014852
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Vogelmeier, Claus $u Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, German Center for Lung Research (DZL), Marburg, Germany.
700    1_
$a Roche, Nicolas $u Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Cochin, University Paris Descartes (EA2511), Paris, France.
700    1_
$a Halpin, David $u Royal Devon and Exeter Hospital, Exeter, UK.
700    1_
$a Cardoso, João $u Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Universidade Nova de Lisboa, Lisbon, Portugal.
700    1_
$a Chuchalin, Alexander G $u Institute of Pulmonology, Federal Medical and Biological Agency, Moscow, Russia.
700    1_
$a Kankaanranta, Hannu $u Dept of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland Dept of Respiratory Medicine, University of Tampere, Tampere, Finland.
700    1_
$a Sandström, Thomas $u Department of Public Health and Clinical Medicine, Medicine Unit, Umeå University, Umeå, Sweden.
700    1_
$a Śliwiński, Paweł $u 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
700    1_
$a Zatloukal, Jaromir $u Dept of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Blasi, Francesco $u Dept of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, Italy.
773    0_
$w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 47, č. 2 (2016), s. 625-37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26797035 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170117122801 $b ABA008
999    __
$a ok $b bmc $g 1179741 $s 961168
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 47 $c 2 $d 625-37 $e 20160121 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...